With an eye on the bottom line, hospitals and their marketing firms traditionally haven't spent much time on school campuses.
An expert tells MM&M a key issue is whether unsubstantiated benefits were used in marketing efforts.
First-quarter results show prescription weight-loss drugs continue to struggle with market and mind share.
Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales
Celltrion expects its Remicade biosimilar to hit the US this year; Vivus cuts its sales force; BMJ accuses Novartis of interfering with clinical trials
Increased FDA scrutiny has not garnered trust for the new medications.
The partners will focus on developing treatments for metabolic disorders.
Doctors tell MM&M that prescription weight-loss medications are just one component of an obesity treatment regimen.
The drugmaker released interim clinical trial information in an SEC filing that the FDA wanted kept quiet until the trial was completed.
FDA clears Novo's liraglutide for obesity; doctors' views vary on Express Scripts' hep.-C plan; Janssen, Gilead advance plans for HIV drugs.
Category news shows that marketing to the obese may mean marketing to related conditions.
Researchers find that jet lag has an impact on the microscopic level.
Although sales have not skyrocketed, Arena and PBM Express Scripts have seen demand for prescription weight-loss medications rise, and researchers at The Obesity Society find the majority of weight-loss intervention candidates are eligible for prescription weight-loss medications.
Takeda and Orexigen's prescription weight-loss drug Contrave has hit the market with a wraparound patient support system.
Takeda's Director of Obesity Marketing Katie Andino told MM&M in a phone interview that the drugmaker will be taking a unique approach to woo patients, physicians and payers.
Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.
The latest data shows an overall widening of the US.
Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.
Diet and exercise can help some type-2 diabetes patients save around $500 in medical expenses every year.
J&J subsidiary Janssen has abandoned its patent lawsuit over the anti-seizure medication topiramate, which is part of Vivus's prescription weight-loss drug Qsymia.
An experimental Gelesis weight-loss drug seeks the middle ground between surgery and appetite suppressants.
Lawmakers criticized Columbia University chairman and professor of surgery Dr. Mehmet Oz for calling weight-loss supplements miracles on his TV program, despite lacking scientific proof to support those claims.
The bad-ad watchdog says the promotional website for the weight-loss medication Suprenza leaves out too much information.
The regulator wants more time to discuss post-marketing requirements.
A study shows that total knee replacement is rising—and occurring in more youthful people. The uptick tracks with the rise in obesity.
Gelesis is pouring money into its obesity "smart pill," and Novo reports weighty success among subjects taking liraglutide.
Eisai announced it was adding sales reps to promote its drug Belviq, while Vivus, maker of Qsymia, fights off a generic marketing application by Actavis.
Arena and Eisai are testing Belviq with appetite suppressant phentermine.
A national survey indicates that obesity rates for children ages 2 to 5 has fallen since the early 2000s, yet overall numbers remain largely unchanged and high.
Analyst Thomas Wei reviews the prescription slimming category and sees two different realities for Vivus and Arena.
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.